住院COVID-19患者的二次和并发感染:马来西亚的一项多中心跨部门研究
Siti Roszilawati Ramli1, Fashihah Sherina Abdul Hadi1, Nur Asyura Nor Amdan1
1Infectious Diseases Research Centre, Institute for Medical Research, National Institutes of Health, Setia Alam, Shah Alam 40170, Malaysia.
在马来西亚,二次细菌和真菌感染发生在2.3%的COVID-19患者中. 这些共同感染在严重病例中更为常见,并且与死亡率增加有关,这突显了需要仔细管理抗生素的必要性.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 公共卫生 公共卫生
背景情况:
- 病毒性呼吸道感染,包括COVID-19,经常因二次细菌和真菌感染而复杂化.
- 了解这些共同感染的发病率和风险因素对于患者管理和抗生素管理至关重要.
研究的目的:
- 确定马来西亚COVID-19患者的细菌和真菌共感染的发生率和相关因素.
- 在COVID-19爆发的第一波和第二波期间分析抗生素处方模式.
主要方法:
- 从3532名入院马来西亚医院的COVID-19患者的临床记录的回顾性分析 (2020年2月至8月).
- 数据收集包括并发病,临床特征,调查和治疗.
- 用WHONET数据库分析了培养和灵敏度结果.
- 单变量和多变量回归分析确定了相关的决定因素.
主要成果:
- 在2.3% (81/3532) 的患者中发现了细菌和真菌感染.
- 常见的细菌分离物包括*Pseudomonas aeruginosa* (15.3%) 和*Klebsiella pneumoniae* (13.9%).这些细菌分离物中含有*Pseudomonas aeruginosa* (15.3%) 和*Klebsiella pneumoniae* (13.9%).
- *Candida albicans* (41.2%) 是最常见的真菌分离物.
- 常被处方的抗生素包括奥格曼丁,塞夫triaxone,tazocin,meropenem和azithromycin (四个是世卫组织"观察"类别).
- 同时感染在重病患者中更为普遍,并与较高的死亡率相关.
结论:
- 在COVID-19患者中,二次细菌和真菌的共同感染是显著的,特别是那些严重生病的人.
- 这些感染与死亡率的增加有关.
- 抗生素处方模式需要审查,特别是在世卫组织"观察"类药物方面.
更多相关视频
12:21A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
Published on: September 28, 2022
10:27In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions
Published on: October 21, 2022
相关概念视频
Pneumonia III: Complications and Assessment
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Single Nucleotide Polymorphisms-SNPs
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
